Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.
But the reasons for its all-stock acquisition of AcroImmune seem more prosaic.
But some phase 3 details are unconfirmed, and phase 2 data haven’t shed light on the biggest question.
BDTX-1535 takes aim at PACC mutations and Tagrisso resistance.
What similarly acting projects are still unpartnered?
Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
